Literature DB >> 15925697

The olfactory bulbectomised rat as a model of depression.

Cai Song1, Brian E Leonard.   

Abstract

Bilateral olfactory bulbectomy results in changes in behavior, and in the endocrine, immune and neurotransmitter systems, that simulates many of those seen in patients with major depression. The olfactory system in the rat forms a part of the limbic region in which the amygdala and hippocampus contribute to the emotional and memory components of behavior. However, the loss of olfaction alone, which results from bulbectomy, is not the major factor that contributes to the behavioral abnormalities as peripherally induced anosmia does not cause the same behavioral changes. Thus it would appear that bulbectomy causes a major dysfunction of the cortical-hippocampal-amygdala circuit that underlies the behavioral and other changes. These neuroanatomical areas also seem to be dysfunctional in the patient with major depression. Chronic, but not acute, administration of antidepressants largely corrects most the behavioral, endocrine, immune and neurotransmitter changes that occur following bulbectomy. Thus the olfactory bulbectomized rat is not only a model for detecting antidepressant activity but also one for exploring the inter-relationships between these systems that are also dysfunctional in patients with major depression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15925697     DOI: 10.1016/j.neubiorev.2005.03.010

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  146 in total

1.  Evaluation of reward processes in an animal model of depression.

Authors:  David A Slattery; Athina Markou; John F Cryan
Journal:  Psychopharmacology (Berl)       Date:  2006-12-20       Impact factor: 4.530

2.  Olfactory system modulation of hippocampal cell death.

Authors:  Kenneth Pope; Donald A Wilson
Journal:  Neurosci Lett       Date:  2007-06-14       Impact factor: 3.046

3.  Role of olfaction in the conditioned sucrose preference of sweet-ageusic T1R3 knockout mice.

Authors:  Steven Zukerman; Khalid Touzani; Robert F Margolskee; Anthony Sclafani
Journal:  Chem Senses       Date:  2009-09-07       Impact factor: 3.160

4.  Animal models of depression: molecular perspectives.

Authors:  Vaishnav Krishnan; Eric J Nestler
Journal:  Curr Top Behav Neurosci       Date:  2011

Review 5.  Neurosteroid, GABAergic and hypothalamic pituitary adrenal (HPA) axis regulation: what is the current state of knowledge in humans?

Authors:  Shannon K Crowley; Susan S Girdler
Journal:  Psychopharmacology (Berl)       Date:  2014-04-23       Impact factor: 4.530

6.  Decreased olfactory bulb volumes in patients with fibromyalgia syndrome.

Authors:  Selçuk Sayılır; Neşat Çullu
Journal:  Clin Rheumatol       Date:  2017-07-26       Impact factor: 2.980

7.  T1R2+T1R3-independent chemosensory inputs contributing to behavioral discrimination of sugars in mice.

Authors:  Lindsey A Schier; Chizuko Inui-Yamamoto; Ginger D Blonde; Alan C Spector
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-01-09       Impact factor: 3.619

8.  An altered spinal serotonergic system contributes to increased thermal nociception in an animal model of depression.

Authors:  Antonio Rodríguez-Gaztelumendi; María Luisa Rojo; Angel Pazos; Alvaro Díaz
Journal:  Exp Brain Res       Date:  2014-03-01       Impact factor: 1.972

9.  Prenatal alcohol exposure increases vulnerability to stress and anxiety-like disorders in adulthood.

Authors:  Kim G C Hellemans; Pamela Verma; Esther Yoon; Wayne Yu; Joanne Weinberg
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

10.  SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model.

Authors:  M E Breuer; M M van Gaalen; W Wernet; S E F Claessens; R S Oosting; B Behl; S M Korte; H Schoemaker; G Gross; B Olivier; L Groenink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-31       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.